Contribute Try STAT+ Today

In a clutch of lawsuits, three drug makers argue the federal government is wrong to insist they must provide discounts on medicines to pharmacies that work with hospitals and clinics that serve primarily low-income populations.

The claims made by AstraZeneca (AZN), Sanofi, (SNY), and Eli Lilly (LLY) follow a recent advisory opinion issued by the Department of Health and Human Services, which maintained drug companies were wrong to curtail price breaks required as part of the 340B drug discount program.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.